Stock listing
Hamburg:1U5 Wave Life Sciences Ltd. Aktie
German listing (Hamburg) of Wave Life Sciences Ltd. · home listing NASDAQ:WVE
Follow Wave Life Sciences Ltd. into a list and get an email when it puts out news.
Home listing price · NASDAQ:WVE
$2.56 USD -0.21 (-7.6%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:WVE
- Day range
- $2.55 – $2.79 USDNov 20, 2026
- Volume
- 2.28M sharesNov 20, 2026
- Market cap
- $504.9M USDAt the close on Nov 20, 2026 · price × 197.2M shares outstanding
- 52-week range
- $2.55 – $21.73 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $12.25M USDMedian day 2.95M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:WVE · Home | $2.56 USD | -0.21 (-7.6%) | 2,279,709 | $2.65 | $2.79 | $2.545 | $2.77 | Close on Nov 20, 2026 |
| Frankfurt:1U5 | €2.30 EUR | -0.07 (-3.0%) | — | €2.27 | €2.30 | €2.27 | €2.37 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:WVE · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.56 | -0.21 | -7.6% | $2.65 | $2.79 | $2.545 | 2,279,709 | |
| $2.77 | -0.07 | -2.5% | $2.85 | $2.94 | $2.75 | 2,206,560 | |
| $2.84 | -0.03 | -1.0% | $2.81 | $2.915 | $2.77 | 2,780,153 | |
| $2.87 | -0.26 | -8.3% | $3.08 | $3.15 | $2.855 | 2,321,398 | |
| $3.13 | -0.025 | -0.8% | $3.12 | $3.195 | $3.00 | 2,656,161 | |
| $3.155 | -0.265 | -7.7% | $3.45 | $3.53 | $3.15 | 2,462,991 | |
| $3.42 | +0.01 | +0.3% | $3.49 | $3.49 | $3.38 | 1,704,598 | |
| $3.41 | -0.07 | -2.0% | $3.40 | $3.558 | $3.321 | 1,400,159 | |
| $3.48 | +0.115 | +3.4% | $3.42 | $3.565 | $3.28 | 3,934,545 | |
| $3.365 | +0.145 | +4.5% | $3.25 | $3.42 | $3.23 | 2,204,914 | |
| $3.22 | -0.40 | -11.0% | $3.59 | $3.615 | $3.18 | 5,317,219 | |
| $3.62 | +0.04 | +1.1% | $3.70 | $3.78 | $3.56 | 2,738,498 | |
| $3.58 | +0.06 | +1.7% | $3.55 | $3.665 | $3.55 | 3,827,068 | |
| $3.52 | -0.07 | -1.9% | $3.64 | $3.69 | $3.43 | 1,941,203 | |
| $3.59 | -0.04 | -1.1% | $3.62 | $3.70 | $3.43 | 3,327,320 | |
| $3.63 | -0.01 | -0.3% | $3.75 | $3.86 | $3.60 | 3,571,422 | |
| $3.64 | +0.19 | +5.5% | $3.44 | $3.765 | $3.36 | 4,257,137 | |
| $3.45 | +0.24 | +7.5% | $3.50 | $3.55 | $3.235 | 4,191,258 | |
| $3.21 | +0.03 | +0.9% | $3.17 | $3.235 | $3.13 | 3,224,124 | |
| $3.18 | -0.17 | -5.1% | $3.33 | $3.34 | $3.12 | 2,655,200 | |
| $3.35 | -0.02 | -0.6% | $3.36 | $3.43 | $3.34 | 1,846,400 | |
| $3.37 | -0.05 | -1.5% | $3.42 | $3.48 | $3.35 | 2,172,900 | |
| $3.42 | +0.25 | +7.9% | $3.18 | $3.49 | $3.18 | 3,615,900 | |
| $3.17 | +0.04 | +1.3% | $3.15 | $3.19 | $3.08 | 1,863,500 | |
| $3.13 | -0.06 | -1.9% | $3.24 | $3.28 | $3.08 | 3,281,800 | |
| $3.19 | +0.10 | +3.2% | $3.13 | $3.23 | $3.08 | 3,351,000 | |
| $3.09 | -0.05 | -1.6% | $3.09 | $3.13 | $3.04 | 2,824,900 | |
| $3.14 | -0.14 | -4.3% | $3.27 | $3.27 | $3.07 | 4,183,400 | |
| $3.28 | -0.18 | -5.2% | $3.46 | $3.46 | $3.27 | 2,256,900 | |
| $3.46 | -0.01 | -0.3% | $3.49 | $3.53 | $3.43 | 1,655,800 | |
| $3.47 | -0.07 | -2.0% | $3.48 | $3.51 | $3.37 | 2,664,300 | |
| $3.54 | +0.02 | +0.6% | $3.48 | $3.60 | $3.43 | 3,052,600 | |
| $3.52 | -0.23 | -6.1% | $3.78 | $3.82 | $3.48 | 3,448,600 | |
| $3.75 | -0.03 | -0.8% | $3.81 | $3.88 | $3.71 | 3,513,200 | |
| $3.78 | -0.10 | -2.6% | $3.89 | $3.96 | $3.77 | 3,743,700 | |
| $3.88 | +0.18 | +4.9% | $3.95 | $4.07 | $3.78 | 5,410,200 | |
| $3.70 | +0.06 | +1.6% | $3.79 | $3.84 | $3.62 | 4,209,300 | |
| $3.64 | -0.03 | -0.8% | $3.67 | $3.78 | $3.56 | 2,765,400 | |
| $3.67 | -0.11 | -2.9% | $3.77 | $3.78 | $3.60 | 3,546,400 | |
| $3.78 | -0.18 | -4.5% | $4.00 | $4.00 | $3.75 | 4,066,600 | |
| $3.96 | +0.01 | +0.3% | $3.96 | $4.01 | $3.82 | 3,155,600 | |
| $3.95 | -0.40 | -9.2% | $4.27 | $4.35 | $3.92 | 3,972,900 | |
| $4.35 | +0.09 | +2.1% | $4.30 | $4.43 | $4.22 | 2,577,900 | |
| $4.26 | -0.09 | -2.1% | $4.44 | $4.45 | $4.20 | 2,372,500 | |
| $4.35 | -0.09 | -2.0% | $4.42 | $4.48 | $4.31 | 4,409,700 | |
| $4.44 | -0.07 | -1.6% | $4.59 | $4.65 | $4.42 | 2,171,800 | |
| $4.51 | +0.05 | +1.1% | $4.55 | $4.60 | $4.42 | 2,990,700 | |
| $4.46 | -0.12 | -2.6% | $4.58 | $4.58 | $4.40 | 2,466,800 | |
| $4.58 | -0.01 | -0.2% | $4.60 | $4.63 | $4.49 | 2,869,900 | |
| $4.59 | -0.08 | -1.7% | $4.67 | $4.72 | $4.56 | 2,207,600 | |
| $4.67 | -0.14 | -2.9% | $4.76 | $4.76 | $4.63 | 2,767,600 | |
| $4.81 | -0.10 | -2.0% | $4.86 | $4.93 | $4.76 | 3,248,700 | |
| $4.91 | +0.05 | +1.0% | $4.86 | $4.97 | $4.75 | 3,557,700 | |
| $4.86 | +0.16 | +3.4% | $4.71 | $4.89 | $4.65 | 3,030,000 | |
| $4.70 | -0.18 | -3.7% | $4.80 | $4.97 | $4.65 | 6,156,700 | |
| $4.88 | -0.09 | -1.8% | $4.95 | $5.09 | $4.66 | 5,478,900 | |
| $4.97 | +0.07 | +1.4% | $4.85 | $4.98 | $4.80 | 3,000,400 | |
| $4.90 | -0.14 | -2.8% | $5.06 | $5.07 | $4.84 | 3,811,600 | |
| $5.04 | -0.12 | -2.3% | $5.16 | $5.22 | $5.03 | 2,250,700 | |
| $5.16 | -0.07 | -1.3% | $5.23 | $5.28 | $5.04 | 2,949,800 | |
| $5.23 | -0.02 | -0.4% | $5.26 | $5.30 | $5.18 | 2,197,200 | |
| $5.25 | +0.13 | +2.5% | $5.12 | $5.35 | $5.12 | 2,413,500 | |
| $5.12 | -0.17 | -3.2% | $5.27 | $5.32 | $5.12 | 4,554,700 | |
| $5.29 | +0.04 | +0.8% | $5.30 | $5.48 | $5.27 | 2,721,900 | |
| $5.25 | -0.17 | -3.1% | $5.41 | $5.47 | $5.18 | 2,660,500 |
- Ticker
- Hamburg:1U5
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Hamburg
- Currency
- EUR
What changed lately
Latest news release · Nov 13, 2026
Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026
Latest earnings call · Oct 27, 2026
Wave Life Sciences (NASDAQ:WVE) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 9, 2026
AASLD 2026
Conference · 16 slides
Latest news
Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026
Nov 13, 2026
Closed $3.13 (-0.8%) on Nov 13, 2026
Wave Life Sciences to Present at Jefferies Global Healthcare Conference in London
Nov 11, 2026
Closed $3.42 (+0.3%) on Nov 11, 2026
Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Oct 27, 2026
Closed $3.45 (+7.5%) on Oct 27, 2026
Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026
Oct 20, 2026
Closed $3.42 (+7.9%) on Oct 20, 2026
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
Oct 19, 2026
Closed $3.17 (+1.3%) on Oct 19, 2026
Wave Life Sciences to Present at Chardan’s 10th Annual Healthcare Conference
Oct 13, 2026
Closed $3.14 (-4.3%) on Oct 13, 2026
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
Oct 1, 2026
Closed $3.88 (+4.9%) on Oct 1, 2026
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
Sep 30, 2026
Closed $3.70 (+1.6%) on Sep 30, 2026
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
Sep 23, 2026
Closed $3.95 (-9.2%) on Sep 23, 2026
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
Sep 22, 2026
Closed $4.35 (+2.1%) on Sep 22, 2026
Wave Life Sciences Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 36 in the last 12 months · 178 in all · newest Nov 13, 2026 · oldest 2019
- Calls
- 25 calls with a replay · 25 with a transcript · latest Oct 27, 2026
- Decks
- 98 decks · latest Nov 9, 2026
Where Wave Life Sciences Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:WVE · Home listing | NASDAQ | United States | USD |
| gettex:1U5 | gettex | Germany | EUR |
| LS Exchange:A1436W | LS Exchange | Germany | EUR |
| Tradegate:1U5 | Tradegate | Germany | EUR |
| BOATS:WVE | BOATS | United States | USD |
| Lang & Schwarz:A1436W | Lang & Schwarz | Germany | EUR |
| Stuttgart:1U5 | Stuttgart | Germany | EUR |
| Frankfurt:1U5 | Frankfurt | Germany | EUR |
| Dusseldorf:1U5 | Dusseldorf | Germany | EUR |
| Hamburg:1U5 · This page | Hamburg | Germany | EUR |
| Munich:1U5 | Munich | Germany | EUR |
Valuation
EV/sales 1.1× against a median of 16.1×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $74.16M USD
- P/E
- Loss
- EV/sales
- 1.1×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 1.3×
- Gross margin
- Not reported
- Operating margin
- −320.9%
- Net margin
- −296.9%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.70
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Wave Life Sciences Ltd. · NASDAQ:WVE | US$504.9M | US$74.16M | n/a | 1.1× | n/a | 1.3× | −296.9% | 0.0× | 1.70 |
| Abbisko Cayman Limited · HKEX:2256 | US$518.9M | US$228.0M | n/a | n/a | n/a | 1.6× | n/a | 0.2× | n/a |
| Alumis Inc. · NASDAQ:ALMS | US$512.6M | US$116.5M | n/a | 16.1× | n/a | 1.4× | n/a | 0.1× | 1.58 |
| Electra Therapeutics, Inc. · NASDAQ:ETRA | US$509.8M | US$107.3M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Adlai Nortye Group Ltd. · NASDAQ:ANL | US$502.2M | US$297.0M | n/a | 59.4× | n/a | 2.3× | −710.6% | 0.1× | 1.96 |
| Steminent Biotherapeutics, Inc. · TPEX:7729 | US$496.9M | US$470.4M | n/a | n/a | n/a | 16.2× | n/a | 0.0× | n/a |
| Xuanzhu Biopharmaceutical Co., Ltd. Class H · HKEX:2575 | US$495.2M | US$407.1M | n/a | 23.2× | n/a | 2.2× | −200.8% | 0.0× | n/a |
| TenNor Therapeutics Suzhou Ltd. Class H · HKEX:6872 | US$489.2M | US$391.6M | n/a | n/a | n/a | 5.0× | n/a | 0.1× | n/a |
| Crescent Biopharma, Inc. · NASDAQ:CBIO | US$482.9M | US$196.0M | n/a | 13.1× | n/a | 1.8× | −727.6% | 0.0× | 0.92 |
| Sana Biotechnology, Inc. · NASDAQ:SANA | US$476.4M | US$408.5M | n/a | n/a | n/a | 2.6× | n/a | 0.3× | 2.29 |
| Regenxbio Inc. · NASDAQ:RGNX | US$473.4M | US$289.0M | n/a | 1.9× | n/a | 3.2× | −113.9% | 0.5× | 1.60 |
| Median of the others | US$496.1M | US$293.0M | 16.1× | 2.3× | −455.7% | 0.1× | 1.60 |
Forecasts
17 strong buy · 2 buy · 2 hold · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 17.05 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.10 · 15 analysts
- Revenue, year to Dec 2026
- 62.97M · 18 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Adrian Rawcliffe | CEO-Partner and Chief Executive Officer |
| Christian Henry | President and Chief Executive Officer, Pacific Biosciences |
| Paul Bolno | President and Chief Executive Officer |
| Linda Rockett | Senior Vice President, General Counsel |
| James Salierno | Director, Investor Relations |
| Kate Rausch | VP, Corporate Affairs and Investor Relations |
| Aik Na Tan | Senior Vice President (Administration), Nanyang Technological University, Singapore |
| Daryn Lewis | Senior Vice President, Head of Human Resources |
| Ginnie Yang | Senior Vice President, Translational Medicine |
| Sridhar Vaddeboina | Senior Vice President, Chemistry, Manufacturing, and Controls |
| Monika Vnuk | Chief Business Officer |
Board
| Director | Role |
|---|---|
| Ken Takanashi | Vice Chairman |
Events
Calls
| Call | When | Status |
|---|---|---|
| Wave Life Sciences (NASDAQ:WVE) Q3 2026 Earnings Call | Tue, Oct 27, 2026 · 8:30 AM ET | Replay |
| Wave Life Sciences (NASDAQ:WVE) Q2 2026 Earnings Call | Thu, Jul 30, 2026 · 8:30 AM ET | Replay |
| Wave Life Sciences (NASDAQ:WVE) Q1 2026 Earnings Call | Tue, Apr 28, 2026 · 8:30 AM ET | Replay |
| Wave Life Sciences (NASDAQ:WVE) Q4 2025 Earnings Call | Thu, Feb 26, 2026 · 8:30 AM ET | Replay |
| Wave Life Sciences (NASDAQ:WVE) Q3 2025 Earnings Call | Mon, Nov 10, 2025 · 8:30 AM ET | Replay |
| Wave Life Sciences (NASDAQ:WVE) Q2 2025 Earnings Call | Wed, Jul 30, 2025 · 8:30 AM ET | Replay |
| Wave Life Sciences (NASDAQ:WVE) Q1 2025 Earnings Call | Thu, May 08, 2025 · 8:30 AM ET | Replay |
| Wave Life Sciences (NASDAQ:WVE) Q4 2024 Earnings Call | Tue, Mar 04, 2025 · 8:30 AM ET | Replay |
| Wave Life Sciences (NASDAQ:WVE) Q3 2024 Earnings Call | Tue, Nov 12, 2024 · 8:30 AM ET | Replay |
| Wave Life Sciences (NASDAQ:WVE) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 8:30 AM ET | Replay |
All 25 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 27, 2026 · Before open | +7.5% |
| Q2 2026 | Jul 30, 2026 · Before open | −0.9% |
| Q1 2026 | Apr 28, 2026 · Before open | +8.4% |
| Q4 2025 | Feb 26, 2026 | −4.2% |
| Q3 2025 | Nov 10, 2025 · Before open | −10.3% |
| Q2 2025 | Jul 30, 2025 · Before open | −1.9% |
| Q1 2025 | May 8, 2025 · Before open | +0.8% |
| Q4 2024 | Mar 4, 2025 | +5.2% |
| Q3 2024 | Nov 12, 2024 · Before open | −3.4% |
| Q2 2024 | Aug 8, 2024 · Before open | −4.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 10, 2024 · Before open | −2.4% |
| Q4 2023 | Mar 6, 2024 · Before open | +31.3% |
| Q3 2023 | Nov 9, 2023 · Before open | −9.6% |
| Q2 2023 | Aug 3, 2023 · Before open | +15.8% |
| Q1 2023 | May 3, 2023 · Before open | +1.9% |
| Q4 2022 | Mar 22, 2023 · Before open | −10.4% |
| Q3 2022 | Nov 10, 2022 · Before open | +5.8% |
| Q2 2022 | Aug 11, 2022 · Before open | +16.9% |
| Q1 2022 | May 12, 2022 · Before open | −12.2% |
| Q4 2021 | Mar 3, 2022 · Before open | −2.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| AASLD 2026 | Conference | 16 slides | Nov 9, 2026 |
| Investor Presentation (July 2026) | Investor deck | 50 slides | Jul 30, 2026 |
| ATS 2026 | Conference | 19 slides | May 18, 2026 |
| Investor Presentation (February 2026) | Investor deck | 49 slides | Feb 26, 2026 |
| Investor Presentation (January 2026) | Investor deck | 62 slides | Jan 12, 2026 |
| Investor Presentation (November 2025) | Investor deck | 58 slides | Nov 17, 2025 |
| ObesityWeek 2025 | Conference | 21 slides | Oct 31, 2025 |
| Investor Presentation (September 2025) | Investor deck | 49 slides | Sep 24, 2025 |
| Investor Presentation (August 2025) | Investor deck | 45 slides | Aug 5, 2025 |
| 85th American Diabetes Association Scientific Sessions (ADA 2025) | Conference | 14 slides | Jun 20, 2025 |
Show 50 decks
This page holds 50 of 98 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Public offering of ordinary shares and pre-funded warrants Made bigger: about US$350M · US$19 a share · Jefferies +4 Dealers: Jefferies (co-lead), Leerink Partners (co-lead), BofA Securities (co-lead), Truist Securities, Mizuho | Dec 9, 2025 |
| At-the-market programme of shares sold under ATM program Tranche closed: US$72.1M raised Use of proceeds: Extend expected cash runway into 2Q 2027 | Nov 10, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Nov 10, 2015.
- Price
- US$16.00 a share
- Shares offered
- 6,375,000 ordinary shares
- Offering size
- US$102 million
- Underwriters' option
- Up to 956,250 more shares
- Underwriters
- Jefferies, Leerink Partners, JMP Securities, SunTrust Robinson Humphrey · In the order on the cover
- Shares delivered
- On or about Nov 16, 2015
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 4, 2015 |
| Filed publicly | Oct 9, 2015 |
| Amended 5 times | Newest Nov 10, 2015 |
| Shares registered with an exchange | Nov 9, 2015 |
| Declared effective by the SEC | Nov 10, 2015 |
| Final prospectus, with the price | Nov 12, 2015 |
Filings
| Filing | Filed |
|---|---|
| CERTNAS · Nasdaq's certificate of listing | Nov 12, 2015 |
| 424B1 · Prospectus | Nov 12, 2015 |
| EFFECT · Notice that a registration is effective | Nov 10, 2015 |
| S-1MEF · Registration of more shares for the same offering | Nov 10, 2015 |
| S-1/A · Registration statement, amended | Nov 10, 2015 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 9, 2015 |
| S-1/A · Registration statement, amended | Nov 9, 2015 |
| S-1/A · Registration statement, amended | Nov 6, 2015 |
| CORRESP · Letter to the SEC | Nov 6, 2015 |
| CORRESP · Letter to the SEC | Nov 6, 2015 |
All 20 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Nov 2, 2015 |
| CORRESP · Letter to the SEC | Oct 23, 2015 |
| S-1/A · Registration statement, amended | Oct 23, 2015 |
| UPLOAD · Letter from the SEC | Oct 20, 2015 |
| S-1 · Registration statement | Oct 9, 2015 |
| DRS/A · Draft registration statement, amended | Oct 2, 2015 |
| UPLOAD · Letter from the SEC | Oct 2, 2015 |
| DRS/A · Draft registration statement, amended | Sep 17, 2015 |
| DRSLTR · Letter to the SEC with a draft | Sep 16, 2015 |
| DRS · Draft registration statement | Sep 4, 2015 |
Open IPO · From the cover of the final prospectus (424B1) filed Nov 12, 2015
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.7M | 108.3M | 113.3M | 3.65M | 41.0M | 20.1M | 16.0M | 14.4M | 3.70M | 1.49M |
| Research and development | 182.8M | 159.7M | 130.0M | 115.9M | 121.9M | 130.9M | 175.4M | 134.4M | 79.3M | 40.8M |
| Operating income | -215.4M | -110.4M | -68.0M | -162.7M | -127.0M | -153.4M | -208.3M | -159.5M | -102.4M | -55.7M |
| Depreciation and amortization | 3.44M | 3.90M | 5.00M | 6.57M | 7.48M | 8.11M | 7.59M | 5.58M | 2.15M | 784.0K |
| EBITDA | -211.9M | -106.5M | -63.0M | -156.1M | -119.5M | -145.3M | -200.7M | -153.9M | -100.2M | -54.9M |
| Income before tax | -204.4M | -97.0M | -58.2M | -161.1M | -122.4M | -150.8M | -193.6M | -146.6M | -101.1M | -55.2M |
| Income tax | 0 | 0 | -677.0K | 681.0K | -204.0K | -841.0K | 0 | 69.0K | 842.0K | 482.0K |
| Net income | -204.4M | -97.0M | -57.5M | -161.8M | -122.2M | -149.9M | -193.6M | -146.7M | -102.0M | -55.7M |
| Earnings per share, basic | -1.21 | -0.70 | -0.54 | -2.05 | -2.36 | -3.82 | -5.72 | -5.06 | -3.85 | -2.44 |
| Earnings per share, diluted | -1.21 | -0.70 | -0.54 | -2.05 | -2.36 | -3.82 | -5.72 | -5.06 | -3.85 | -2.44 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 602.1M | 302.1M | 200.4M | 88.5M | 150.6M | 184.5M | 147.2M | 174.8M | 142.5M | 150.3M |
| Short-term investments | 0 | |||||||||
| Receivables | 1.28M | 1.42M | 21.1M | 30.0M | 20.0M | 10.0M | 1.00M | |||
| Current assets | 614.8M | 320.4M | 235.4M | 98.5M | 162.6M | 230.0M | 185.5M | 202.3M | 150.5M | 152.0M |
| Property, plant and equipment | 7.41M | 10.1M | 13.1M | 17.3M | 22.3M | 29.2M | 36.4M | 39.9M | 27.3M | 8.61M |
| Total assets | 638.5M | 352.2M | 274.9M | 146.4M | 207.0M | 279.2M | 284.3M | 295.9M | 181.8M | 164.8M |
| Accounts payable | 15.7M | 16.3M | 12.8M | 16.9M | 7.28M | 13.8M | 9.07M | 13.1M | 7.60M | 4.94M |
| Current liabilities | 95.1M | 111.0M | 186.4M | 71.5M | 64.2M | 121.0M | 118.2M | 130.0M | 18.2M | 12.2M |
| Total liabilities | 112.3M | 134.8M | 227.4M | 183.6M | 166.6M | 188.6M | 212.6M | 214.7M | 34.4M | 22.1M |
| Shareholders' equity | 518.4M | 209.5M | 39.6M | -45.1M | 32.5M | 82.8M | 63.7M | 73.3M | 139.6M | 134.6M |
| Shares outstanding | 0 | 153.0M | 119.2M | 86.9M | 59.8M | 48.8M | 34.3M | 29.5M | 27.8M | 23.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -187.5M | -151.0M | -19.4M | -127.8M | -89.0M | -116.0M | -188.2M | -22.9M | -83.7M | -31.9M |
| Capital spending | -718.0K | -938.0K | -1.11M | -1.36M | -560.0K | -1.34M | -3.92M | -9.94M | -18.9M | -5.57M |
| Free cash flow | -188.2M | -152.0M | -20.5M | -129.1M | -89.6M | -117.3M | -192.1M | -32.8M | -102.6M | -37.5M |
| Cash from investing | -718.0K | -938.0K | -1.11M | -1.25M | -560.0K | -1.34M | -3.92M | -9.94M | -18.9M | -5.56M |
| Cash from financing | 488.2M | 253.9M | 132.5M | 67.2M | 55.8M | 154.5M | 164.4M | 65.1M | 94.4M | 29.1M |
| Change in cash | 300.0M | 101.8M | 111.9M | -62.1M | -33.9M | 37.3M | -27.6M | 32.3M | -7.78M | -8.38M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 18, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Oct 27, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 27, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Oct 14, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Oct 14, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 12, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 11, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 11, 2026 | Other filings | SEC |
| 15-12G | Aug 7, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Aug 7, 2026 | Offer document | SEC |
| POSASR | Aug 7, 2026 | Other filings | SEC |
| S-8 POS | Aug 7, 2026 | Offer document | SEC |
| S-8 POS | Aug 7, 2026 | Offer document | SEC |
| S-8 POS | Aug 7, 2026 | Offer document | SEC |
| S-8 POS | Aug 7, 2026 | Offer document | SEC |
| S-8 POS | Aug 7, 2026 | Offer document | SEC |
| S-8 POS | Aug 7, 2026 | Offer document | SEC |
| S-8 POS | Aug 7, 2026 | Offer document | SEC |
| S-8 POS | Aug 7, 2026 | Offer document | SEC |
| S-8 POS | Aug 7, 2026 | Offer document | SEC |
| S-8 POS | Aug 7, 2026 | Offer document | SEC |
| S-8 POS | Aug 7, 2026 | Offer document | SEC |
| S-8 POS | Aug 7, 2026 | Offer document | SEC |
| S-8 POS | Aug 7, 2026 | Offer document | SEC |
| S-8 POS | Aug 7, 2026 | Offer document | SEC |
| S-8 POS | Aug 7, 2026 | Offer document | SEC |
| S-8 POS | Aug 7, 2026 | Offer document | SEC |
| 8-K12B | Aug 7, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2026 | Results | SEC |
| 8-K · Current report | Jun 26, 2026 | Meeting outcome | SEC |
| 8-K · Current report | May 18, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | May 7, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | May 5, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 1, 2026 | Other filings | SEC |
| PRER14A | May 1, 2026 | Other filings | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2026 | Annual report | SEC |
| UPLOAD · Letter from the SEC | Apr 30, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Apr 28, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 28, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 21, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Apr 17, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 17, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 17, 2026 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 15, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 15, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 15, 2026 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 26, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 9, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 5, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 2, 2026 | Current report | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 15, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Dec 10, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 10, 2025 | Material contract | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 424B5 · Prospectus | Dec 8, 2025 | Offer document | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 8, 2025 | Current report | SEC |
| 8-K · Current report | Nov 17, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 13, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Nov 10, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Nov 10, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| 8-K/A · Current report, amended | Oct 30, 2025 | Current report | SEC |
| 8-K · Current report | Oct 29, 2025 | Current report | SEC |
| 8-K · Current report | Sep 24, 2025 | Current report | SEC |
| 8-K · Current report | Sep 3, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 13, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 11, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 5, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Jul 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Jun 23, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Jun 23, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 13, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 20, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 7, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 4, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 4, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 25, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 20, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 15, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Nov 12, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Nov 12, 2024 | Offer document | SEC |
| S-3ASR · Registration statement | Nov 12, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 144 · Notice of proposed sale | Nov 8, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 30, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 18, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Oct 18, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Oct 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 16, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 16, 2024 | Current report | SEC |
| 8-K · Current report | Oct 15, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 1, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 1, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 1, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | Sep 27, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 26, 2024 | Material contract | SEC |
| 144 · Notice of proposed sale | Sep 25, 2024 | Other filings | SEC |
| 424B5 · Prospectus | Sep 24, 2024 | Offer document | SEC |
This page holds 200 of 745 filings. Open Filings
Cap table
Built by 6ix from Wave Life Sciences Ltd.’s releases · as of Nov 10, 2025
- Common shares
- 197,228,968
- Fully diluted
- 197,228,968
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 197,228,968 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 197,228,968 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Peter Kolchinsky Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Black Diamond Therapeutics, Inc. (Director · Jul 5, 2023 – Jul 5, 2023 · Past); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Research Alliance Corp II (Chief Executive Officer, Director · Mar 17, 2021 – Mar 17, 2021 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Solid Biosciences Inc. (Director · Dec 10, 2020 – Jan 11, 2024 · Past); POINT Biopharma Global Inc (Chief Executive Officer, Director · Jul 7, 2020 – Jun 29, 2021 · Past); Forma Therapeutics Holdings Inc (Director · Jun 18, 2020 – Jun 8, 2022 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 3, 2022 · Past); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past); Kala Bio, Inc. (Director · Oct 3, 2018 – Mar 13, 2020 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – Jun 19, 2018 · Past); KalVista Pharmaceuticals, Inc. (Director · Oct 12, 2017 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Jun 20, 2017 – Apr 2, 2020 · Past); Dicerna Pharmaceuticals Inc (Director · Jan 29, 2014 – Nov 27, 2019 · Past) | Director · Since at least Aug 14, 2015 |
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Since at least Aug 16, 2021 |
| Mark Corrigan Other companies: Trevena, Inc. (Director · Jul 18, 2023 – Jun 13, 2024 · Past); Novelion Therapeutics Inc (Director · Mar 30, 2017 – Aug 9, 2018 · Past); Nabriva Therapeutics AG (Director · Dec 30, 2016 – Aug 2, 2022 · Past); CoLucid Pharmaceuticals Inc (Director · Oct 27, 2015 – Mar 1, 2017 · Past); Avanir Pharmaceuticals Inc (Director · Mar 18, 2014 – Mar 18, 2014 · Past); EPIRUS Biopharmaceuticals Inc (Director · Dec 21, 2009 – Jun 5, 2015 · Past); Cubist Pharmaceuticals Inc (Director · Jun 20, 2008 – Jan 21, 2015 · Past); Sepracor Inc (Executive VP, R&D · Mar 16, 2006 – Oct 20, 2009 · Past) | Director · Since at least Sep 4, 2019 |
| Christian Henry Other companies: Ginkgo Bioworks Holdings, Inc. (Director · Since at least Sep 16, 2021); Pacific Biosciences of California, Inc. (Director · Since at least Jul 27, 2018); CM Life Sciences III Inc. (Director · Apr 6, 2021 – Apr 6, 2021 · Past); Illumina, Inc. (EVP & Chief Commercial Officer · Jun 14, 2013 – Jan 30, 2017 · Past) | President and Chief Executive Officer, Pacific Biosciences · Since at least Nov 10, 2016 |
| Adrian Rawcliffe Other companies: Adaptimmune Therapeutics PLC (Chief Executive Officer, Director · Jan 1, 2016 – Feb 20, 2025 · Past); Human Genome Sciences Inc (Chief Financial Officer, Director · Jul 30, 2012 – Jul 30, 2012 · Past) | CEO-Partner and Chief Executive Officer · Since at least Feb 1, 2017 |
| Christopher Wright Other companies: Alkermes plc (Director · Since at least May 24, 2022); Cyclerion Therapeutics, Inc. (Chief Medical Officer · Feb 25, 2021 – Feb 25, 2021 · Past) | Chief Medical Officer · Since at least May 28, 2025 |
| Michael A. Panzara Other companies: Immunic, Inc. (Chief Medical Officer · Since at least Apr 24, 2026); LeonaBio, Inc. (Director · Since at least Mar 18, 2022) | See Remarks · Feb 1, 2021 – Jul 25, 2022 · Past |
| Amy Pott Other companies: enGene Therapeutics Inc. (Chief Global Comm. Ofc. · Since at least May 27, 2025) | Director · Sep 4, 2019 – Aug 18, 2020 · Past |
| Heidi L. Wagner Other companies: Alexion Pharmaceuticals Inc (SVP, Global Government Affairs · Oct 1, 2015 – Feb 27, 2018 · Past) | Director · Since at least Sep 4, 2019 |
| Keith Regnante Other companies: Keros Therapeutics, Inc. (CHIEF FINANCIAL OFFICER · Since at least Apr 7, 2020) | Chief Financial Officer · Aug 16, 2016 – Mar 7, 2019 · Past |
All 30 people
| Person | Seat |
|---|---|
| Ken Takanashi Other companies: Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past) | Director · Since at least Aug 14, 2015 |
| Mark Baldry Other companies: X4 Pharmaceuticals, Inc. (Chief Commercial Officer · Nov 3, 2022 – May 16, 2025 · Past) | Chief Commerical Officer · Aug 5, 2019 – Aug 5, 2019 · Past |
| Paul B. Bolno Other companies: Invivyd, Inc. (Director · Since at least Sep 22, 2025) | President and Chief Executive Officer · Since at least Nov 10, 2015 |
| Roberto Guerciolini Other companies: Sirna Therapeutics Inc (Senior VP Development & CMO · Feb 21, 2006 – Dec 29, 2006 · Past) | See Remarks · Nov 10, 2015 – Dec 7, 2016 · Past |
| Aik Na Tan | Senior Vice President (Administration), Nanyang Technological University, Singapore · Since at least Aug 18, 2020 |
| Chandra Vargeese | See Remarks · Since at least Nov 10, 2015 |
| Chris Francis | See Remarks · Since at least Nov 10, 2015 |
| Daryn Lewis | Senior Vice President, Head of Human Resources · Since at least Nov 4, 2026 |
| Erik Ingelsson | Chief Scientific Officer · Since at least Apr 9, 2026 |
| Ginnie Yang | Senior Vice President, Translational Medicine · Since at least Nov 4, 2025 |
| Gregory L Verdine | Director · Since at least Jun 16, 2016 |
| James Salierno | Director, Investor Relations · Since at least Oct 27, 2026 |
| Kate Rausch | VP, Corporate Affairs and Investor Relations · Since at least Oct 27, 2026 |
| Ken Takanashi | Vice Chairman · Since at least Oct 7, 2026 |
| Koji Miura | Director · Nov 10, 2015 – Aug 15, 2019 · Past |
| Kyle Moran | Chief Financial Officer · Since at least Nov 10, 2015 |
| Linda Rockett | Senior Vice President, General Counsel · Since at least Nov 4, 2026 |
| Masaharu Tanaka | Director · Aug 14, 2015 – Sep 15, 2017 · Past |
| Monika Vnuk | Chief Business Officer · Since at least Sep 22, 2026 |
| Sridhar Vaddeboina | Senior Vice President, Chemistry, Manufacturing, and Controls · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Wave Life Sciences Ltd.